Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
View Patent ↗The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
1. A method for inducing a protective immune response in a pre-weaned porcine animal against infection by a Porcine Reproductive and Respiratory Syndrome (PRRS) virus, the method comprising administering to said animal a vaccine comprising a modified live PRRS virus, and a carrier suitable for veterinary use,
wherein said vaccine is administered to said animal at two weeks of age or less; wherein said vaccine is safe and immunoprotective even if administered when said animal is no more than one day of age;
wherein said modified live PRRS virus is prepared by passaging a virulent PRRS virus a plurality of times in a permissive mammalian non-macrophage cell line that exogenously expresses porcine CD163 receptor protein, and recovering virus from the culture; and
wherein said protective immune response provides a reduction in lung lesions during PRRS infection in comparison to an unvaccinated animal infected with PRRS.
2. The method of claim 1 wherein the duration of said protective immune response is up to 6 months.
3. The method of claim 1 , wherein said vaccine further comprises an immunoprotection-inducing Mycoplasma hyopneumoniac antigen, an immunoprotection-inducing Porcine Circovirus Type 2 antigen, or a combination thereof.
4. A method for inducing a protective immune response in a porcine animal against infection by a Porcine Reproductive and Respiratory Syndrome (PRRS) virus, the method comprising administering to said animal, prior to weaning, a vaccine comprising:
(a) a modified live PRRS virus,
(b) an infectious RNA molecule encoding said modified PRRS virus,
(c) an isolated polynucleotide molecule comprising a DNA sequence encoding said infectious RNA molecule,
(d) a viral vector comprising said infectious RNA molecule, or
(e) a viral vector comprising said isolated polynucleotide molecule;
and a carrier suitable for veterinary use;
wherein said vaccine is administered to said animal at two weeks of age or less;
wherein said modified PRRS virus is prepared by passaging a virulent PRRS virus a plurality of times on permissive mammalian non-macrophage cells exogenously expressing porcine CD163 receptor;
wherein said modified PRRS virus exhibits reduced virulence in said animal in comparison to a wild-type or unmodified PRRS virus from which the modified virus was derived; and
wherein said administration induces a protective immune response in a porcine animal against infection by a wild-type PRRS virus, wherein said protective immune response provides a reduction in lung lesions during PRRS infection in comparison to an unvaccinated animal infected with PRRS.
5. The method of claim 1 wherein said vaccine comprises a modified live European PRRS virus.
6. The method of claim 4 wherein said vaccine comprises a modified live European PRRS virus.
7. The method of claim 1 wherein said vaccine comprises a modified live North American PRRS virus.
8. The method of claim 4 wherein said vaccine comprises a modified live North American PRRS virus.
9. The method of claim 4 , wherein the duration of protecting immunity is up to 6 months.
10. The method of claim 4 , wherein said vaccine provides a duration of immunity for up to 6 months, when vaccination is administered on day 1 of life.
11. The method of claim 1 , wherein said vaccine is administered to said animal at one week of age or less.